Literature DB >> 24980541

Aneuploidy and skeletal health.

Archana Kamalakar1, John R Harris, Kent D McKelvey, Larry J Suva.   

Abstract

The normal human chromosome complement consists of 46 chromosomes comprising 22 morphologically different pairs of autosomes and one pair of sex chromosomes. Variations in either chromosome number and/or structure frequently result in significant mental impairment and/or a variety of other clinical problems, among them, altered bone mass and strength. Chromosomal syndromes associated with specific chromosomal abnormalities are classified as either numerical or structural and may involve more than one chromosome. Aneuploidy refers to the presence of an extra copy of a specific chromosome, or trisomy, as seen in Down's syndrome (trisomy 21), or the absence of a single chromosome, or monosomy, as seen in Turner syndrome (a single X chromosome in females: 45, X). Aneuploidies have diverse phenotypic consequences, ranging from severe mental retardation and developmental abnormalities to increased susceptibility to various neoplasms and premature death. In fact, trisomy 21 is the prototypical aneuploidy in humans, is the most common genetic abnormality associated with longevity, and is one of the most widespread genetic causes of intellectual disability. In this review, the impact of trisomy 21 on the bone mass, architecture, skeletal health, and quality of life of people with Down syndrome will be discussed.

Entities:  

Mesh:

Year:  2014        PMID: 24980541      PMCID: PMC4136427          DOI: 10.1007/s11914-014-0221-4

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  63 in total

1.  Bone mineral mass in males and females with and without Down syndrome.

Authors:  Fatima Baptista; Ana Varela; Luis B Sardinha
Journal:  Osteoporos Int       Date:  2004-09-09       Impact factor: 4.507

2.  Slipped capital femoral epiphysis in patients with Down syndrome.

Authors:  Patrick Bosch; Charles E Johnston; Lori Karol
Journal:  J Pediatr Orthop       Date:  2004 May-Jun       Impact factor: 2.324

Review 3.  The interaction between dietary protein and bone health.

Authors:  David Jesudason; Peter Clifton
Journal:  J Bone Miner Metab       Date:  2010-10-26       Impact factor: 2.626

Review 4.  Surgical challenges and clinical outcomes of total hip replacement in patients with Down's syndrome.

Authors:  M G Zywiel; M A Mont; J J Callaghan; J C Clohisy; Y Kosashvili; D Backstein; A E Gross
Journal:  Bone Joint J       Date:  2013-11       Impact factor: 5.082

5.  Bone mass, gonadal function and biochemical assessment in young men with trisomy 21.

Authors:  Athanasios Sakadamis; Nickoletta Angelopoulou; Chrysoula Matziari; Vasilios Papameletiou; Vasilios Souftas
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2002-01-10       Impact factor: 2.435

6.  Rates of trisomies 21, 18, 13 and other chromosome abnormalities in about 20 000 prenatal studies compared with estimated rates in live births.

Authors:  D M Schreinemachers; P K Cross; E B Hook
Journal:  Hum Genet       Date:  1982       Impact factor: 4.132

7.  Fracture epidemiology and control in a developmental center.

Authors:  G S Lohiya; F M Crinella; L Tan-Figueroa; S Caires; S Lohiya
Journal:  West J Med       Date:  1999-04

8.  Risks of leukaemia and solid tumours in individuals with Down's syndrome.

Authors:  H Hasle; I H Clemmensen; M Mikkelsen
Journal:  Lancet       Date:  2000-01-15       Impact factor: 79.321

9.  Hypothalamic versus pituitary dysfunction in Down's syndrome as cause of growth retardation.

Authors:  S Castells; I Beaulieu; C Torrado; K E Wisniewski; S Zarny; M C Gelato
Journal:  J Intellect Disabil Res       Date:  1996-12

10.  Low bone turnover and low bone density in a cohort of adults with Down syndrome.

Authors:  K D McKelvey; T W Fowler; N S Akel; J A Kelsay; D Gaddy; G R Wenger; L J Suva
Journal:  Osteoporos Int       Date:  2012-08-18       Impact factor: 4.507

View more
  6 in total

1.  Low bone mass and impaired fracture healing in mouse models of Trisomy21 (Down syndrome).

Authors:  Kirby M Sherman; Diarra K Williams; Casey A Welsh; Alexis M Cooper; Alyssa Falck; Shannon Huggins; Rihana S Bokhari; Dana Gaddy; Kent D McKelvey; Lindsay A Dawson; Larry J Suva
Journal:  Bone       Date:  2022-06-15       Impact factor: 4.626

Review 2.  Skeletal dynamics of Down syndrome: A developing perspective.

Authors:  Jonathan M LaCombe; Randall J Roper
Journal:  Bone       Date:  2019-12-27       Impact factor: 4.398

Review 3.  Current Analysis of Skeletal Phenotypes in Down Syndrome.

Authors:  Jared R Thomas; Randall J Roper
Journal:  Curr Osteoporos Rep       Date:  2021-04-08       Impact factor: 5.163

4.  Spina bifida-predisposing heterozygous mutations in Planar Cell Polarity genes and Zic2 reduce bone mass in young mice.

Authors:  Isabel R Orriss; Stuart Lanham; Dawn Savery; Nicholas D E Greene; Philip Stanier; Richard Oreffo; Andrew J Copp; Gabriel L Galea
Journal:  Sci Rep       Date:  2018-02-20       Impact factor: 4.379

5.  Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.

Authors:  Jared R Thomas; Kourtney Sloan; Kelsey Cave; Joseph M Wallace; Randall J Roper
Journal:  Genes (Basel)       Date:  2021-10-28       Impact factor: 4.141

6.  Sclerostin Antibody Treatment Stimulates Bone Formation to Normalize Bone Mass in Male Down Syndrome Mice.

Authors:  Diarra K Williams; Sean G Parham; Eric Schryver; Nisreen S Akel; R Shane Shelton; Jessica Webber; Francis L Swain; Jami Schmidt; Larry J Suva; Dana Gaddy
Journal:  JBMR Plus       Date:  2017-12-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.